BR112022018529A2 - Usos de conjugado de hialuronano - Google Patents

Usos de conjugado de hialuronano

Info

Publication number
BR112022018529A2
BR112022018529A2 BR112022018529A BR112022018529A BR112022018529A2 BR 112022018529 A2 BR112022018529 A2 BR 112022018529A2 BR 112022018529 A BR112022018529 A BR 112022018529A BR 112022018529 A BR112022018529 A BR 112022018529A BR 112022018529 A2 BR112022018529 A2 BR 112022018529A2
Authority
BR
Brazil
Prior art keywords
hyaluronan
hyaluronan conjugate
conjugate
conjugate uses
treatment
Prior art date
Application number
BR112022018529A
Other languages
English (en)
Inventor
Lin Hua-Yang
Original Assignee
Aihol Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aihol Corp filed Critical Aihol Corp
Publication of BR112022018529A2 publication Critical patent/BR112022018529A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

USOS DE CONJUGADO DE HIALURONANO. A presente invenção refere-se ao uso de um conjugado de hialuronano para o tratamento de inflamação pulmonar, incluindo inflamação pulmonar aguda e crônica. Também é descrito no presente o uso de um conjugado de hialuronano para o tratamento de infecção por vírus. O conjugado de hialuronano é um conjugado de ácido hialurônico (HA)-nimesulida.
BR112022018529A 2020-06-08 2021-06-08 Usos de conjugado de hialuronano BR112022018529A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036231P 2020-06-08 2020-06-08
US202063130442P 2020-12-24 2020-12-24
PCT/US2021/036438 WO2021252513A1 (en) 2020-06-08 2021-06-08 Uses of hyaluronan conjugate

Publications (1)

Publication Number Publication Date
BR112022018529A2 true BR112022018529A2 (pt) 2022-12-13

Family

ID=78818452

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018529A BR112022018529A2 (pt) 2020-06-08 2021-06-08 Usos de conjugado de hialuronano

Country Status (10)

Country Link
US (2) US11643431B2 (pt)
EP (1) EP4146231A1 (pt)
JP (1) JP7483050B2 (pt)
KR (1) KR20220146486A (pt)
CN (1) CN115209904A (pt)
AU (1) AU2021289350B2 (pt)
BR (1) BR112022018529A2 (pt)
CA (1) CA3170553A1 (pt)
TW (1) TWI833088B (pt)
WO (1) WO2021252513A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220146486A (ko) * 2020-06-08 2022-11-01 아이홀 코포레이션 히알루로난 접합체의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0422877D0 (en) * 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers
ITPD20050242A1 (it) * 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
ES2326721B1 (es) * 2008-01-04 2010-07-16 Endor Nanotechnologies, S.L. Conjugado de acido hialuronico para el tratamiento cosmetico y procedimiento de preparacion.
JP5587049B2 (ja) 2010-06-21 2014-09-10 株式会社 糖質科学研究所 低分子ヒアルロン酸の製造方法
CN103381152A (zh) * 2013-02-05 2013-11-06 吉林省金梓源生物科技有限公司 杨梅素作为组织蛋白酶k抑制剂的用途
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
EP3325325B1 (en) * 2015-07-17 2023-09-06 Harsco Technologies LLC Rail warning system
KR20220146486A (ko) * 2020-06-08 2022-11-01 아이홀 코포레이션 히알루로난 접합체의 용도

Also Published As

Publication number Publication date
JP7483050B2 (ja) 2024-05-14
TWI833088B (zh) 2024-02-21
AU2021289350A1 (en) 2022-09-15
TW202203974A (zh) 2022-02-01
AU2021289350B2 (en) 2023-10-19
CN115209904A (zh) 2022-10-18
US20210380625A1 (en) 2021-12-09
EP4146231A1 (en) 2023-03-15
CA3170553A1 (en) 2021-12-16
KR20220146486A (ko) 2022-11-01
US20230227490A1 (en) 2023-07-20
WO2021252513A1 (en) 2021-12-16
US11643431B2 (en) 2023-05-09
JP2023524081A (ja) 2023-06-08

Similar Documents

Publication Publication Date Title
MX2022010659A (es) Compuestos altamente activos contra la enfermedad por coronavirus de 2019 (covid-19).
BR112023000323A2 (pt) Vacina combinada contra sars-cov-2 e influenza
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112022017891A2 (pt) Métodos para tratar a infecção por coronavírus e lesão pulmonar induzida por inflamação resultante
BR112017017500A2 (pt) derivado de quinolina para uso no tratamento e prevenção de infecções virais
BRPI1016257B8 (pt) composições compreendendo finafloxacina para tratamento de infecções óticas
BR112022018529A2 (pt) Usos de conjugado de hialuronano
BR112015014243A8 (pt) composição de vacina para uso em populações imunocomprometidas e uso da mesma
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
BR112019022307A2 (pt) Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza.
BR112022021748A2 (pt) Compostos e composições para inibir a atividade de hif2a e seus métodos de uso
BR112018006276A2 (pt) composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv.
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
BRPI0418103A (pt) extrato aquoso do córtex da canela, uso de um extrato de canela, composição, métodos para o tratamento de um paciente que esteja sofrendo de infecção viral e para desinfetar uma área suspeita de ter sido contaminada com vìrus, filtro, método para produzir um vìrus neutralizado para imunização, vìrus neutralizado, formulação de vacina e, método de imunização contra infecção viral
BR112015023806A2 (pt) Novos regimes de dosagem de celgosivir para o tratamento de dengue
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
CL2008001282A1 (es) Composicion farmaceutica con actividad antimicrobiana que comprende un aminoacidos n halogenado y un agente antiinflamatorio; uso para prevenir o tratar una infeccion de tejidos, donde dicho tejido es ocular, nasal, seno nasal o dermico o una infeccion respiratoria.
BR112022018504A2 (pt) Usos de uma composição
BR112022021284A2 (pt) Composição farmacêutica, seu uso para tratar ou prevenir um câncer induzido pelo vírus do papiloma humano, e combinação
BR112019018028A2 (pt) Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BR112022000971A2 (pt) Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv
BR112021020496A2 (pt) Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo
BRPI0620983B8 (pt) uso de derivados de triazina para fabricação de um medicamento, e composição farmacêutica para uso tópico
EA202191482A1 (ru) Другие гетероароматические соединения, обладающие активностью против rsv